(function(){ var content_array=[" \n

埃博拉病毒<\/span><\/b>簡<\/span><\/b>介<\/span><\/b><\/span><\/p> \n

埃博拉出血<\/span>熱<\/span>(Ebola HF)<\/span>是人<\/span>類<\/span>和非人靈<\/span>長類動<\/span>物(猴子、大猩猩和黑猩猩)中偶<\/span>發<\/span>的<\/span>嚴<\/span>重且常常致命的疾病,<\/span>1976<\/span>年首次<\/span>發現<\/span>。埃博拉出血<\/span>熱<\/span>的潛伏期<\/span>為<\/span>2<\/span>至<\/span>21<\/span>天。埃博拉出血<\/span>熱<\/span>患者會突然出<\/span>現發熱<\/span>、<\/span>頭<\/span>痛、關<\/span>節<\/span>和肌肉疼痛、喉<\/span>嚨<\/span>痛、極度乏力等症狀,隨後會腹瀉、嘔吐、腹痛。西非爆<\/span>發<\/span>的疫情(首例<\/span>報<\/span>告於<\/span>2014<\/span>年<\/span>3<\/span>月)是<\/span>1976<\/span>年首次<\/span>發現<\/span>埃博拉病毒以來全球出<\/span>現<\/span>的<\/span>規<\/span>模最大、最<\/span>為<\/span>復<\/span>雜<\/span>的埃博拉疫情。此次疫情中出<\/span>現<\/span>的病例數和死亡人數超<\/span>過<\/span>了<\/span>歷<\/span>次<\/span>總<\/span>和。埃博拉<\/span>還<\/span>在西非國家<\/span>間<\/span>蔓延,從幾內<\/span>亞<\/span>開始蔓延到塞拉利昂和利比裡<\/span>亞<\/span>,通<\/span>過<\/span>航空運<\/span>輸<\/span>波及到尼日利<\/span>亞<\/span>和美國,又通<\/span>過陸<\/span>地交通<\/span>傳<\/span>播到塞內加<\/span>爾<\/span>和<\/span>馬<\/span>裡。<\/span><\/span><\/p> \n

皮卡佐<\/span><\/b>劑<\/span><\/b>技<\/span><\/b>術簡<\/span><\/b>介<\/span><\/b><\/span><\/p> \n

皮卡佐<\/span>劑<\/span>技<\/span>術<\/span>是依生生物自主開<\/span>發<\/span>、具有自主知<\/span>識產權<\/span>的<\/span>專<\/span>利技<\/span>術<\/span>。<\/span>這<\/span>種佐<\/span>劑<\/span>是雙<\/span>鏈<\/span>RNA<\/span>類<\/span>似物,作<\/span>為<\/span>Toll<\/span>樣<\/span>受體<\/span>3(TLR-3)<\/span>配體來激活先天免疫<\/span>細<\/span>胞,如<\/span>樹<\/span>突<\/span>細<\/span>胞、巨噬<\/span>細<\/span>胞和<\/span>NK<\/span>細<\/span>胞。能<\/span>產<\/span>生<\/span>強<\/span>烈的特異性<\/span>T<\/span>細<\/span>胞免疫<\/span>應<\/span>答。在攻毒<\/span>實驗<\/span>中<\/span>產<\/span>生<\/span>顯<\/span>著的治<\/span>療<\/span>保<\/span>護<\/span>效力。<\/span><\/span><\/p> \n

美國<\/span><\/b>陸軍傳<\/span><\/b>染病醫學研究所<\/span><\/b>(USAMRIID)<\/span><\/b>簡<\/span><\/b>介<\/span><\/b><\/span><\/p> \n

美國<\/span>陸軍傳<\/span>染病醫學研究所<\/span>(USAMRIID)<\/span>肩<\/span>負<\/span>著以<\/span>領<\/span>先的醫<\/span>療<\/span>能力防控新老生物威<\/span>脅<\/span>制<\/span>劑<\/span>的使命。<\/span>該<\/span>機構開展的研究<\/span>為<\/span>人<\/span>們帶<\/span>來了<\/span>許<\/span>多<\/span>創<\/span>新的醫<\/span>療產<\/span>品,例如疫苗、<\/span>藥<\/span>品、<\/span>診<\/span>斷和信息等,造福於<\/span>維護軍<\/span>事人<\/span>員<\/span>和平民百姓的身體健康。作<\/span>為<\/span>防恐怖威<\/span>脅<\/span>署的<\/span>Joint Science and Technology Office for Chemical and Biological Defense<\/span>(化學和生物國防<\/span>聯<\/span>合科技<\/span>辦<\/span>公室)的主要<\/span>軍<\/span>事醫學研究<\/span>實驗<\/span>室,<\/span>該<\/span>研究所<\/span>發揮<\/span>著關<\/span>鍵<\/span>作用。<\/span>USAMRIID<\/span>是美國<\/span>陸軍<\/span>醫<\/span>療<\/span>研究與裝<\/span>備<\/span>司令部<\/span>(U.S. Army Medical Research and Materiel Command)<\/span>下屬的<\/span>實驗<\/span>室。<\/span><\/span><\/p> \n

(本新<\/span>聞<\/span>稿中的信息不一定反映政府的立<\/span>場<\/span>或政策,<\/span>應<\/span>推斷<\/span>為<\/span>尚無官方<\/span>認<\/span>可。)<\/span><\/span><\/p> \n

依生生物制<\/span><\/b>藥<\/span><\/b>有限公司<\/span><\/b>簡<\/span><\/b>介<\/span><\/b><\/span><\/p> \n

依生生物制<\/span>藥<\/span>有限公司<\/span>總<\/span>部位於中國北京大<\/span>興<\/span>生物醫<\/span>藥產業<\/span>基地,主要從事生物疫苗<\/span>產<\/span>品的研究、開<\/span>發<\/span>、生<\/span>產<\/span>、<\/span>銷<\/span>售和市<\/span>場營銷<\/span>,在中國、美國和新加坡<\/span>設<\/span>有分公司,<\/span>擁<\/span>有大<\/span>約<\/span>1000<\/span>名<\/span>員<\/span>工。<\/span><\/span><\/p> \n

www.yishengbio.com<\/span><\/a><\/p>"]; $("#dvExtra").html(content_array[0]);})();